Innoviva Signs Exclusive Distribution Agreement with Dr. Reddy's for XACDURO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Innoviva Specialty Therapeutics, a subsidiary of Innoviva (INVA), announced that it has entered into an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories (RDY) for the development and commercialization of XACDURO, co-packaged for intravenous use, in South and Central America, the Caribbean, Russia and Commonwealth of Independent States countries. Under the terms of the agreement, Dr. Reddy's will be responsible for development, regulatory and commercialization activities in the licensed territory. Innoviva Specialty Therapeutics will retain rights to XACDURO in all unlicensed territories and is eligible to receive an upfront payment, regulatory and commercial milestone payments, and tiered royalties on net sales in the licensed territory.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INVA
Wall Street analysts forecast INVA stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 22.610
Low
31.00
Averages
37.33
High
46.00
Current: 22.610
Low
31.00
Averages
37.33
High
46.00
About INVA
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dauntless Investment Group Increases Stake in Innoviva
- Increased Holdings: Dauntless Investment Group acquired an additional 116,863 shares of Innoviva in Q1 2026, valued at approximately $2.52 million, indicating confidence in the company's growth potential.
- Stock Performance: As of last Friday, Innoviva's stock was priced at $21.42, reflecting a 10% increase over the past year, yet underperforming the S&P 500's 28% gain, suggesting market undervaluation of its potential.
- Financial Highlights: Innoviva reported an 11% year-over-year revenue increase to $98 million in Q1, driven by a 37% surge in net product sales to $41.4 million from its Innoviva Specialty Therapeutics business, showcasing its competitive edge in the respiratory drug market.
- Strategic Investments: The management highlighted a robust cash position of $603 million and a $20.4 million stock buyback during the quarter, reflecting a proactive approach to capital management and shareholder returns.
See More
Innoviva Q1 Earnings Beat Expectations
- Earnings Beat: Innoviva reported a Q1 GAAP EPS of $2.22, exceeding expectations by $1.83, which indicates a significant improvement in profitability and boosts investor confidence.
- Revenue Growth: The revenue of $97.99 million reflects a 10.6% year-over-year increase, yet it missed expectations by $3.57 million, suggesting that increased market competition may be impacting sales performance.
- Investor Engagement: Innoviva's presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference enhances its visibility among investors, potentially paving the way for future financing and partnership opportunities.
- Financial Transparency: The availability of historical financial data provides investors with a comprehensive analysis foundation, aiding in the assessment of Innoviva's long-term growth potential and market positioning.
See More
Three Affordable Small-Cap Stocks That Deserve Another Look
P/E Ratio Overview: The price-to-earnings (P/E) ratio is a key metric for evaluating a company's valuation, with the average P/E ratio for S&P 500 stocks around 27x. Stocks with a P/E below 12x may offer value, often found among smaller companies that attract less institutional investment.
Innoviva's Unique Business Model: Innoviva, a biotechnology company, operates with a three-part business model and has shown strong revenue growth. It is becoming less reliant on royalty revenue, which has decreased from 72% to 60%, indicating diversification in its income sources.
Wendy's Challenges and Opportunities: Wendy's is facing declining sales and earnings, attributed to reduced consumer dining out. However, it is controlling its operations by shutting underperforming restaurants and showing solid international growth, alongside a high dividend yield of over 8%.
Nabors Industries and Oil Market Trends: Nabors Industries, an oil and gas drilling services company, is experiencing gains due to rising oil prices. Analysts are optimistic about its potential, although the stock's price targets suggest limited upside, making it a speculative pick in the current market.
See More
Innoviva CEO Outlines Three-Part Growth Plan and $125M Buyback
- Business Transformation: Innoviva CEO Pavel Raifeld highlighted the company's evolution from a royalty-focused model to a three-part structure including respiratory royalties, a specialty therapeutics platform, and strategic healthcare investments, with last year's royalty revenue reaching $250 million, demonstrating resilience and growth potential.
- Specialty Therapeutics Growth: Innoviva Specialty Therapeutics achieved nearly $120 million in U.S. sales last year, with expectations to reach at least $150 million this year, marking the third consecutive year of 50% annual growth, indicating a strengthening market position in critical care.
- Strategic Asset Valuation: Raifeld noted that the company's strategic healthcare assets are currently valued at over $600 million, with recent momentum driven by clinical progress at Armata, showcasing the investment potential and future growth opportunities in the biopharmaceutical sector.
- Shareholder Return Plan: Innoviva's announcement of a $125 million share repurchase program reflects the company's confidence in its growth outlook while also indicating its flexibility in capital allocation, allowing for swift action when suitable opportunities arise.
See More
Innoviva Reports Strong Q4 Earnings Results
- Earnings Per Share: Innoviva reported a GAAP EPS of $1.94 for Q4, exceeding market expectations and indicating a significant improvement in profitability, which may attract increased investor interest.
- Revenue Growth: The company achieved revenue of $114.6 million in Q4, reflecting strong demand for its products and reinforcing its position in the industry, which could lead to further market share gains.
- Financial Health: With the increase in revenue and EPS, Innoviva's financial condition continues to improve, enhancing its capacity for future investments and expansions, potentially driving stock price appreciation.
- Market Reaction Outlook: Given the strong earnings report, market sentiment towards Innoviva's future growth is optimistic, likely promoting positive stock performance and attracting more institutional investor interest.
See More
INVA Stock Fluctuates: 52-Week Low at $16.52
- Stock Fluctuation: INVA's 52-week low is $16.52, with a high of $22.76, and the last trade at $19.30 indicates volatility within this range, reflecting cautious market sentiment towards the stock.
- Market Trend: The current price of $19.30 is below the 200-day moving average, suggesting a cautious investor sentiment in the short term, necessitating close monitoring of future market performance to assess investment risks.
- Investor Attention: The fluctuation in INVA's stock price may influence investor decisions, especially in the current economic climate, prompting investors to closely watch market dynamics to adjust their strategies.
- Technical Analysis: The stock's movement between $16.52 and $22.76 indicates a divergence in market expectations for INVA's future performance, leading investors to consider technical indicators to guide trading decisions.
See More
Dauntless Investment Group Increases Stake in Innoviva
- Increased Holdings: Dauntless Investment Group acquired an additional 116,863 shares of Innoviva in Q1 2026, valued at approximately $2.52 million, indicating confidence in the company's growth potential.
- Stock Performance: As of last Friday, Innoviva's stock was priced at $21.42, reflecting a 10% increase over the past year, yet underperforming the S&P 500's 28% gain, suggesting market undervaluation of its potential.
- Financial Highlights: Innoviva reported an 11% year-over-year revenue increase to $98 million in Q1, driven by a 37% surge in net product sales to $41.4 million from its Innoviva Specialty Therapeutics business, showcasing its competitive edge in the respiratory drug market.
- Strategic Investments: The management highlighted a robust cash position of $603 million and a $20.4 million stock buyback during the quarter, reflecting a proactive approach to capital management and shareholder returns.
See More
Innoviva Q1 Earnings Beat Expectations
- Earnings Beat: Innoviva reported a Q1 GAAP EPS of $2.22, exceeding expectations by $1.83, which indicates a significant improvement in profitability and boosts investor confidence.
- Revenue Growth: The revenue of $97.99 million reflects a 10.6% year-over-year increase, yet it missed expectations by $3.57 million, suggesting that increased market competition may be impacting sales performance.
- Investor Engagement: Innoviva's presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference enhances its visibility among investors, potentially paving the way for future financing and partnership opportunities.
- Financial Transparency: The availability of historical financial data provides investors with a comprehensive analysis foundation, aiding in the assessment of Innoviva's long-term growth potential and market positioning.
See More
Three Affordable Small-Cap Stocks That Deserve Another Look
P/E Ratio Overview: The price-to-earnings (P/E) ratio is a key metric for evaluating a company's valuation, with the average P/E ratio for S&P 500 stocks around 27x. Stocks with a P/E below 12x may offer value, often found among smaller companies that attract less institutional investment.
Innoviva's Unique Business Model: Innoviva, a biotechnology company, operates with a three-part business model and has shown strong revenue growth. It is becoming less reliant on royalty revenue, which has decreased from 72% to 60%, indicating diversification in its income sources.
Wendy's Challenges and Opportunities: Wendy's is facing declining sales and earnings, attributed to reduced consumer dining out. However, it is controlling its operations by shutting underperforming restaurants and showing solid international growth, alongside a high dividend yield of over 8%.
Nabors Industries and Oil Market Trends: Nabors Industries, an oil and gas drilling services company, is experiencing gains due to rising oil prices. Analysts are optimistic about its potential, although the stock's price targets suggest limited upside, making it a speculative pick in the current market.
See More
Innoviva CEO Outlines Three-Part Growth Plan and $125M Buyback
- Business Transformation: Innoviva CEO Pavel Raifeld highlighted the company's evolution from a royalty-focused model to a three-part structure including respiratory royalties, a specialty therapeutics platform, and strategic healthcare investments, with last year's royalty revenue reaching $250 million, demonstrating resilience and growth potential.
- Specialty Therapeutics Growth: Innoviva Specialty Therapeutics achieved nearly $120 million in U.S. sales last year, with expectations to reach at least $150 million this year, marking the third consecutive year of 50% annual growth, indicating a strengthening market position in critical care.
- Strategic Asset Valuation: Raifeld noted that the company's strategic healthcare assets are currently valued at over $600 million, with recent momentum driven by clinical progress at Armata, showcasing the investment potential and future growth opportunities in the biopharmaceutical sector.
- Shareholder Return Plan: Innoviva's announcement of a $125 million share repurchase program reflects the company's confidence in its growth outlook while also indicating its flexibility in capital allocation, allowing for swift action when suitable opportunities arise.
See More
Innoviva Reports Strong Q4 Earnings Results
- Earnings Per Share: Innoviva reported a GAAP EPS of $1.94 for Q4, exceeding market expectations and indicating a significant improvement in profitability, which may attract increased investor interest.
- Revenue Growth: The company achieved revenue of $114.6 million in Q4, reflecting strong demand for its products and reinforcing its position in the industry, which could lead to further market share gains.
- Financial Health: With the increase in revenue and EPS, Innoviva's financial condition continues to improve, enhancing its capacity for future investments and expansions, potentially driving stock price appreciation.
- Market Reaction Outlook: Given the strong earnings report, market sentiment towards Innoviva's future growth is optimistic, likely promoting positive stock performance and attracting more institutional investor interest.
See More
INVA Stock Fluctuates: 52-Week Low at $16.52
- Stock Fluctuation: INVA's 52-week low is $16.52, with a high of $22.76, and the last trade at $19.30 indicates volatility within this range, reflecting cautious market sentiment towards the stock.
- Market Trend: The current price of $19.30 is below the 200-day moving average, suggesting a cautious investor sentiment in the short term, necessitating close monitoring of future market performance to assess investment risks.
- Investor Attention: The fluctuation in INVA's stock price may influence investor decisions, especially in the current economic climate, prompting investors to closely watch market dynamics to adjust their strategies.
- Technical Analysis: The stock's movement between $16.52 and $22.76 indicates a divergence in market expectations for INVA's future performance, leading investors to consider technical indicators to guide trading decisions.
See More
